Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
Public ClinicalTrials.gov record NCT00000636. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate and compare the effectiveness of a 2-month regimen of rifampin and pyrazinamide versus a 1-year course of isoniazid (INH) to prevent the development of tuberculosis in patients who are coinfected with HIV and latent Mycobacterium tuberculosis (MTb). Current guidelines recommend 6 to 12 months of treatment with INH for purified protein derivative (PPD)-positive individuals. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to INH-resistant organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more effective than longer courses of INH. A two-month prevention course should help to increase compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome problems with drug resistance.
Study identification
- NCT ID
- NCT00000636
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 2,000 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Oct 1997 (Actual)
- Last update posted
- Nov 2, 2021
Ends 1997
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Community Consortium / UCSF | San Francisco | California | 94110 | — |
| Denver CPCRA / Denver Public Hlth | Denver | Colorado | 802044507 | — |
| Hill Health Corp | New Haven | Connecticut | 06519 | — |
| Wilmington Hosp / Med Ctr of Delaware | Wilmington | Delaware | 19899 | — |
| Veterans Administration Med Ctr / Regional AIDS Program | Washington D.C. | District of Columbia | 20422 | — |
| AIDS Research Consortium of Atlanta | Atlanta | Georgia | 30308 | — |
| Chicago Dept of Health / Speciality STD Clinic | Chicago | Illinois | 60605 | — |
| AIDS Research Alliance - Chicago | Chicago | Illinois | 60657 | — |
| Louisiana Comm AIDS Rsch Prog / Tulane Univ Med | New Orleans | Louisiana | 70112 | — |
| Johns Hopkins Univ / Brazil | Baltimore | Maryland | 21205 | — |
| Johns Hopkins Univ / School of Hygiene & Public Health | Baltimore | Maryland | 21205 | — |
| Boston Dept of Health and Hosps | Boston | Massachusetts | 02118 | — |
| Comprehensive AIDS Alliance of Detroit | Detroit | Michigan | 48201 | — |
| Henry Ford Hosp | Detroit | Michigan | 48202 | — |
| Southern New Jersey AIDS Cln Trials / Dept of Med | Camden | New Jersey | 08103 | — |
| Saint Michael's Med Ctr | Newark | New Jersey | 07102 | — |
| Lattimore Comprehensive Pulmonary Disease Clinic | Newark | New Jersey | 07103 | — |
| North Jersey Community Research Initiative | Newark | New Jersey | 07103 | — |
| Addiction Research and Treatment Corp | Brooklyn | New York | 11201 | — |
| Clinical Directors Network of Region II | New York | New York | 10011 | — |
| Beth Israel Med Ctr | New York | New York | 10035 | — |
| Harlem AIDS Treatment Group / Harlem Hosp Ctr | New York | New York | 10037 | — |
| Bronx Lebanon Hosp Ctr | The Bronx | New York | 10456 | — |
| Philadelphia FIGHT | Philadelphia | Pennsylvania | 19107 | — |
| Richmond AIDS Consortium | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00000636, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 2, 2021 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00000636 live on ClinicalTrials.gov.